Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01392521
Title Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | DEU


No variant requirements are available.